全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...
华西医学  2014 

氯吡格雷抵抗与老年急性冠状动脉综合征患者心血管事件相关性研究

DOI: 10.7507/1002-0179.20140443, PP. 1439-1442

Keywords: 急性冠状动脉综合征,氯吡咯雷抵抗,主要心脏不良事件,血小板聚集率,老年

Full-Text   Cite this paper   Add to My Lib

Abstract:

目的 探讨氯吡格雷抵抗对高龄老年急性冠状动脉综合征患者长期心血管事件的影响。方法 选择2009年1月-2010年12月入住解放军总医院心内科病房300例急性冠状动脉综合征患者为研究对象,年龄70~95岁,平均(81.3±6.4)岁。所有研究对象均接受氯吡格雷片75mg,1次/d,至少服用1个月以上,采用以二磷酸腺苷作为底物的光比浊法检测患者服用氯吡格雷前和服用7d后血小板聚集率的变化情况。按照血小板聚集率变化情况进行试验分组,血小板聚集率降低程度<10%为氯吡格雷抵抗组,≥10%为氯吡格雷非抵抗组。随访主要心血管不良事件(包括心血管病死亡、非致死性心肌梗死、再发心绞痛、缺血性脑卒中/短暂性脑缺血发作、急性血栓形成及出血并发症)的发生情况,随访中位时间为2年。采用Cox风险回归模型评估氯吡咯雷抵抗与心血管事件的关系。结果 氯吡格雷抵抗的发生率为24.0%。患有糖尿病、肾功能不全及体质量指数增高患者易于发生氯吡格雷抵抗,氯吡格雷抵抗患者心血管主要不良事件发生率明显增加(37.5%、22.8%,P=0.032),Cox风险回归方程提示氯吡格雷抵抗是心血管事件发生的独立危险因素HR=2.34,95%CI(1.07,4.57),P=0.016。结论 老年急性冠状动脉综合征患者糖尿病、肾功能不全及体质量指数增高与氯吡格雷抵抗相关,氯吡格雷抵抗患者发生心血管不良事件的风险明显增加。

References

[1]  [ 1 ] Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation[J]. N Engl J Med, 2001, 345(7): 494-502.
[2]  [ 2 ] Steinhubl SR, Berger PB, Mann JT 3rd, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial[J]. JAMA, 2002, 288(19): 2411-2420.
[3]  [ 3 ] Coccheri S. Antiplatelet therapy: controversial aspects[J]. Thromb Res, 2012, 129(3): 225-229.
[4]  [ 4 ] Snoep JD, Hovens MM, Eikenboom JC, et al. Clopidogrel nonresponsivenesa in patients undergoing percutsneous coronary intervention with atenting:a systematic review and mets-analysis[J]. Am Heart J, 2007, 154(2): 221-231.
[5]  [ 5 ] Geisler T, Schaeffeler E, Dippon J, et al. CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation[J]. Pharmacogenomics, 2008, 9(9): 1251-1259.
[6]  [ 6 ] Ferreiro JL, Angiolillo DJ. Challenges and perspectives of antiplatelet therapy in patients with diabetes mellitus and coronary artery disease[J]. Curr Pharm Des, 2012,18(33): 5273-5293.
[7]  [ 7 ] Mangiacapra F, Patti G, Peace A, et al. Comparison of platelet reactivity and periprocedural outcomes in patients with versus without diabetes mellitus and treated with clopidogrel and percutaneous coronary intervention[J]. Am J Cardiol, 2010, 106(5): 619-623.
[8]  [ 8 ] Silva FB, Almeida Junior GL, Neno A, et al.Resistance to clopidogrel: prevalence and associate variables[J]. Arq Bras Cardiol, 2012, 99(6): 1135-1141.
[9]  [ 9 ] 李蕾, 韩江莉, 李海燕, 等. 抗血小板药物抵抗对急性心肌梗死患者再发心脏缺血事件的预价值[J]. 中华医学杂志, 2012, 92(38): 2677-2680.
[10]   Park J, Shin DH, Kim BK. et al. Relationship between aspirin/clopidogrel resistance and intra-stent thrombi assessed by follow-up optical coherence tomography after drug-eluting stent implantation[J]. Eur Heart J Cardiovasc Imaging, 2013, 14(12): 1181-1186.
[11]   Mobley JE, Bresee SJ, Wortham DC, et al. Frequency of nonresponse antiplatelet activity of clopidogrel during pretreatment for cardiac catheterization[J]. Am J Cardiol, 2004, 93(4): 456-458.
[12]   Al-Azzam SI, Alzoubi KH, Khabour OF, et al. Factors that contribute to clopidogrel resistance in cardiovascular disease patients: environmental and genetic approach[J]. Int J Clin Pharmacol Ther, 2013, 51(3): 179-186.

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133